halofuginone has been researched along with Bone Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amiaud, J; Brion, R; Heymann, D; Lamora, A; Mullard, M; Redini, F; Verrecchia, F | 1 |
| Chirgwin, JM; Davis, HW; Fournier, PG; Guise, TA; Javelaud, D; Juárez, P; Mauviel, A; McKenna, RC; Mohammad, KS; Niewolna, M; Peng, XH; Yin, JJ | 1 |
2 other study(ies) available for halofuginone and Bone Neoplasms
| Article | Year |
|---|---|
Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Remodeling; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Osteosarcoma; Piperidines; Quinazolinones; Signal Transduction; Transfection | 2015 |
Halofuginone inhibits the establishment and progression of melanoma bone metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Nude; Piperidines; Quinazolinones; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |